PharmaCorp Rx Inc. (PCRX.V) has had a tough week, with its stock price dropping by 4.08%.
Despite a significant revenue increase in its latest financial results, PharmaCorp's stock has not responded well in the market. Investors may be questioning the impact of recent company announcements and technical indicators.
Investor takeaway: Although PharmaCorp's recent financial results show growth, the stock's price movement suggests caution. Investors should weigh the company's fundamentals against market sentiment before making any decisions.
Advertisement
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$92.58M
52W high
$0.58
52W low
$0.40
1W change
+0.00%
Beta
-4.29
Analyst Price Targets
Based on analyst covering PCRX
Wall Street analysts forecast PCRX stock price to rise 41.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+41.9% Upside
Current Price
C$0.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
33.2%
Annualized
90-Day Vol
59.2%
Annualized
Trend (90d)
-26.0%
Annualized drift
90d Mean
C$0.43
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.46 | C$0.41 โ C$0.51 |
| 60 trading days | C$0.44 | C$0.38 โ C$0.52 |
| 90 trading days | C$0.43 | C$0.35 โ C$0.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
PharmaCorp's stock is currently trading at C$0.47, down 4.08% this week.
The stock has a 52-week range of C$0.40 to C$0.58, indicating it is currently at 39% of its range, with a market cap of approximately C$92.6 million.
Bull case
PharmaCorp reported a remarkable 75.8% increase in revenue and a 78.2% rise in gross profit for Q2 2026 compared to the previous year. This highlights the company's potential for growth. Recent acquisitions and public offerings could also strengthen its market position.
Bear case
Despite the positive revenue growth, the stock has underperformed. Its low trading volume compared to the 20-day average may signal a lack of investor confidence. Additionally, negative profit margins and return on equity complicate the outlook further.
Recent Price Action
Advertisement
PharmaCorp Rx Inc. (PCRX.V) closed at C$0.47, showing no change on the last trading day. However, over the past week, the stock has declined by 4.08%. Year-to-date, PharmaCorp's stock is down 2.08%, indicating a challenging environment for investors.
Company News and Catalysts
PharmaCorp recently announced its second-quarter 2026 financial results, showcasing a substantial 75.8% increase in revenue and a 78.2% rise in gross profit compared to the same quarter in 2025. The company has also made headlines with its recent C$11.5 million and C$10 million bought deal public offerings aimed at supporting growth initiatives. Furthermore, PharmaCorp has completed the acquisition of pharmacy files in Western Canada, enhancing its market presence.
Technical Picture
The technical indicators for PharmaCorp show a last closing price of C$0.47, which is below the 50-day moving average of C$0.50, indicating a bearish trend in the short term. The stock is trading at the lower end of its 52-week range of C$0.40 to C$0.58, currently at 39% of this range. The 200-day moving average is at C$0.47, suggesting that the stock is at a critical juncture. With a beta of -4.29, the stock is less volatile than the market, but the low trading volume of 5,275 shares compared to the 20-day average of 161,339 shares raises concerns about liquidity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
